Candel Therapeutics (CADL) CTO sells 7,000 shares in planned trade

Rhea-AI Filing Summary

Candel Therapeutics, Inc. Chief Technology Officer Tyagarajan Seshu reported an open-market sale of 7,000 shares of common stock at a weighted average price of $10.0216 per share on June 29, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 16, 2026.

After this transaction, Seshu directly holds 83,865 shares of Candel Therapeutics common stock. The price reflected a range of individual trades between $10.00 and $10.07 per share.

Insider Trade Summary 10b5-1

Net Seller: 7,000 shares ($70,151)

Net Sell 1 txn

Insider Tyagarajan Seshu

Role Chief Technology Officer

Sold 7,000 shs ($70K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,000	$10.0216	$70K

Holdings After Transaction: Common Stock — 83,865 shares (Direct, null)

Footnotes (1)

1. This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.

Key Figures

Shares sold: 7,000 shares Average sale price: $10.0216 per share Price range: $10.00–$10.07 per share +2 more

5 metrics

Shares sold 7,000 shares Open-market sale of common stock on June 29, 2026

Average sale price $10.0216 per share Weighted average price for the 7,000 shares sold

Price range $10.00–$10.07 per share Range of individual transaction prices for the sale

Post-transaction holdings 83,865 shares Direct ownership after the reported sale

Trading plan adoption date March 16, 2026 Adoption date of Rule 10b5-1 plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:22 PM Accepted by SEC EDGAR 07/01/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tyagarajan Seshu

(Last) (First) (Middle)

C/O CANDEL THERAPEUTICS, INC.

117 KENDRICK ST., SUITE 450

(Street)

NEEDHAM MASSACHUSETTS 02494

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		S(1)		7,000	D	$10.0216(2)	83,865	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.

	/s/ Charles Schoch, as Attorney-in-Fact for Seshu Tyagarajan	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Candel Therapeutics (CADL) disclose on this Form 4?

Candel Therapeutics reported that Chief Technology Officer Tyagarajan Seshu sold 7,000 shares of common stock. The open-market sale occurred at a weighted average price of $10.0216 per share, with individual trades between $10.00 and $10.07.

What price did the Candel Therapeutics (CADL) insider receive for the shares sold?

The insider sale was executed at a weighted average price of $10.0216 per share. According to the disclosure, the 7,000 shares were sold in multiple trades within a price range of $10.00 to $10.07 per share.

How many Candel Therapeutics (CADL) shares does the CTO hold after this sale?

Following the reported transaction, Chief Technology Officer Tyagarajan Seshu directly holds 83,865 shares of Candel Therapeutics common stock. This post-transaction holding figure comes directly from the Form 4 ownership table after accounting for the 7,000 shares sold.

Was the Candel Therapeutics (CADL) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on March 16, 2026. Such pre-arranged plans allow insiders to systematically sell shares according to preset instructions, independent of subsequent market conditions.

Who is the reporting person in this Candel Therapeutics (CADL) Form 4 filing?

The reporting person is Tyagarajan Seshu, Chief Technology Officer of Candel Therapeutics, Inc. The Form 4 identifies him as an officer of the company and shows a direct ownership position in the common stock after the reported sale.